Brought to you by 
Shire pays $50 per share for ViroPharma
27 Aug 2020
Executive Summary
Further enhancing its rare disease business, Shire PLC is paying $50 per share (a 29% premium) in cash to acquire all the outstanding stock of orphan disease firm ViroPharma Inc., valuing the transaction at $3.3bn.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Shire pays $50 per share for ViroPharma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice